IgA Nephropathy: An Interesting Autoimmune Kidney Disease

Area of Science:

• Nephrology
• Immunology
• Pathophysiology

Background:

• Immunoglobulin A nephropathy (IgAN) is the most prevalent primary glomerulonephritis globally.
• It is a major contributor to chronic kidney disease (CKD) and end-stage kidney disease (ESKD), with up to 40% of patients progressing within 20 years.
• IgAN is linked to substantial patient mortality and diagnostic challenges due to the lack of specific biomarkers, necessitating kidney biopsy.

Purpose of the Study:

• To review the multifaceted aspects of Immunoglobulin A nephropathy.
• To highlight recent advances in understanding IgAN pathophysiology and epidemiology.
• To discuss emerging therapeutic strategies currently in clinical trials.

Main Methods:

• This review synthesizes current scientific literature on IgAN.
• It examines epidemiological data, clinical presentations, and progression patterns.
• The review incorporates recent findings on the disease's autoimmune underpinnings, including the proposed four-hit hypothesis.

Main Results:

• IgAN exhibits significant heterogeneity across diverse populations in its epidemiology, clinical course, and outcomes.
• Advances in understanding IgAN pathophysiology point towards an autoimmune basis, detailed by the four-hit hypothesis.
• Despite no current disease-specific treatments, novel therapeutic approaches are under active investigation in clinical trials.

Conclusions:

• Immunoglobulin A nephropathy remains a significant global health challenge requiring improved diagnostic tools and targeted treatments.
• The proposed autoimmune pathogenesis offers a framework for developing new therapeutic avenues.
• Ongoing clinical trials represent a promising future for IgAN management and improved patient outcomes.